What did @adamvanspanje actually say?
The creator describes ipamorelin as "the most selective GH-secretagogue" and calls it "one of the cleanest growth hormone peptides." The central claim is that it stimulates growth hormone release "without significantly affecting other hormones like cortisol and prolactin," unlike older compounds like GHRP-6 or GHRP-2. He also explains that ipamorelin is often paired with CJC-1295 because the two act on different receptors, ghrelin versus GHRH, to produce a stronger GH pulse. He closes with a brief legal disclaimer noting it is not approved in Australia for therapeutic use.
To his credit, the creator does not make explicit disease claims, does not quote doses, and actually includes a regulatory disclaimer. That puts this video in a different category from a lot of peptide content on TikTok, which tends to promise specific outcomes with zero caveats.
Does the science back this up?
Mostly, yes, with important limits. The selectivity claim is the most defensible part. Early preclinical work established ipamorelin's receptor profile pretty clearly.
A 1998 study by Raun et al. in the European Journal of Endocrinology directly compared ipamorelin to GHRP-6 and GHRP-2 in rats and found that ipamorelin produced robust GH release with significantly smaller cortisol and ACTH responses. That study is the origin of most of the "clean peptide" language you see repeated online, and the creator is summarising it fairly accurately.
The combination rationale with CJC-1295 also has mechanistic logic behind it. Ipamorelin acts on the ghrelin receptor (GHSR-1a), while CJC-1295 is a GHRH analogue acting on the GHRH receptor. These are distinct signalling pathways, and combining them can produce additive or synergistic GH release, as reviewed by Sigalos and Pastuszak in Drugs in R&D (2018). That said, most of this evidence is animal or small-sample human data. Long-term safety data in healthy adults simply does not exist at the level needed to call this compound well-characterised.
What did they get wrong (or right)?
The "without the side effects" framing is where this video oversells. The Raun 1998 data showed reduced cortisol response compared to GHRP-6, not zero effect. Saying it avoids side effects is a different claim from saying it has a cleaner hormonal profile than older compounds.
There is also a real gap between "studies show" and "this is proven safe in humans at clinically relevant doses over time." The creator leans on study language without specifying that most ipamorelin research is preclinical or short-duration. He does not claim it cures anything and does not push doses, which matters. But the "no side effects" shorthand is misleading because known effects still include water retention, transient headaches, and injection-site reactions, and the long-term GH axis effects are not well studied in otherwise healthy people.
Giving credit where it is due: the regulatory disclosure at the end is accurate and relatively clear for a 60-second TikTok.
What should you actually know?
Ipamorelin's selectivity advantage is real but should not be confused with a proven safety record. "Cleaner than GHRP-6" is not the same thing as safe for general use.
In Australia, ipamorelin is not TGA-approved and access through compounding pharmacies falls under specific prescribing conditions. Using it outside of that pathway is a regulatory and clinical risk. The creator mentions this, which is accurate.
Anyone considering ipamorelin should understand that the evidence base is largely animal studies and short human trials, primarily in growth-hormone-deficient populations, not healthy adults pursuing body composition or recovery goals. The Sigalos and Pastuszak review (2018) is one of the few reasonable summaries of GH secretagogue data in humans, and even it flags the thin clinical trial landscape for these compounds. If you are weighing peptide therapy, the conversation needs to start with baseline blood work and a prescribing clinician, not a TikTok explainer.